Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1882 1
1900 1
1921 1
1924 1
1937 1
1941 2
1942 2
1943 2
1944 1
1945 2
1946 7
1947 16
1948 14
1949 8
1950 7
1951 15
1952 11
1953 16
1954 12
1955 12
1956 9
1957 14
1958 12
1959 8
1960 14
1961 15
1962 21
1963 13
1964 30
1965 35
1966 43
1967 37
1968 40
1969 36
1970 42
1971 44
1972 56
1973 68
1974 54
1975 61
1976 54
1977 50
1978 50
1979 53
1980 46
1981 50
1982 51
1983 46
1984 53
1985 55
1986 58
1987 57
1988 54
1989 59
1990 92
1991 62
1992 73
1993 59
1994 55
1995 84
1996 74
1997 92
1998 91
1999 81
2000 93
2001 112
2002 81
2003 102
2004 96
2005 95
2006 132
2007 110
2008 113
2009 136
2010 154
2011 155
2012 145
2013 177
2014 153
2015 184
2016 169
2017 140
2018 157
2019 159
2020 143
2021 144
2022 144
2023 141
2024 171
2025 124

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,460 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV; AQUILA Investigators. Dimopoulos MA, et al. Among authors: baker ri. N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9. N Engl J Med. 2025. PMID: 39652675 Clinical Trial.
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Risse ML, Asset G, Macé S, Martin T; IKEMA study group. Moreau P, et al. Among authors: baker r. Lancet. 2021 Jun 19;397(10292):2361-2371. doi: 10.1016/S0140-6736(21)00592-4. Epub 2021 Jun 4. Lancet. 2021. PMID: 34097854 Clinical Trial.
Skin Care for the Extremely Low-Birthweight Infant.
Visscher MO, McKeown K, Nurre M, Strange R, Mahan T, Kinnett M, Campbell D, Baker RB, Narendran V. Visscher MO, et al. Among authors: baker rb. Neoreviews. 2023 Apr 1;24(4):e229-e242. doi: 10.1542/neo.24-4-e229. Neoreviews. 2023. PMID: 37002398 Review.
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Martin T, et al. Among authors: baker r. Blood Cancer J. 2023 May 9;13(1):72. doi: 10.1038/s41408-023-00797-8. Blood Cancer J. 2023. PMID: 37156782 Free PMC article. Clinical Trial.
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Kuter DJ, et al. Among authors: baker r. N Engl J Med. 2022 Apr 14;386(15):1421-1431. doi: 10.1056/NEJMoa2110297. N Engl J Med. 2022. PMID: 35417637 Clinical Trial.
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
Kuter DJ, Mayer J, Efraim M, Bogdanov LH, Baker R, Kaplan Z, Garg M, Trněný M, Choi PY, Jansen AJG, McDonald V, Bird R, Gumulec J, Kostal M, Gernsheimer T, Ghanima W, Daak A, Cooper N. Kuter DJ, et al. Among authors: baker r. Blood Adv. 2024 Apr 9;8(7):1715-1724. doi: 10.1182/bloodadvances.2023012044. Blood Adv. 2024. PMID: 38386978 Free PMC article. Clinical Trial.
Selective control of parasitic nematodes using bioactivated nematicides.
Burns AR, Baker RJ, Kitner M, Knox J, Cooke B, Volpatti JR, Vaidya AS, Puumala E, Palmeira BM, Redman EM, Snider J, Marwah S, Chung SW, MacDonald MH, Tiefenbach J, Hu C, Xiao Q, Finney CAM, Krause HM, MacParland SA, Stagljar I, Gilleard JS, Cowen LE, Meyer SLF, Cutler SR, Dowling JJ, Lautens M, Zasada I, Roy PJ. Burns AR, et al. Among authors: baker rj. Nature. 2023 Jun;618(7963):102-109. doi: 10.1038/s41586-023-06105-5. Epub 2023 May 24. Nature. 2023. PMID: 37225985
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.
Yong K, Martin T, Dimopoulos MA, Mikhael J, Capra M, Facon T, Hajek R, Špička I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Macé S, Risse ML, Moreau P. Yong K, et al. Among authors: baker r. Lancet Haematol. 2024 Oct;11(10):e741-e750. doi: 10.1016/S2352-3026(24)00148-0. Epub 2024 Jul 24. Lancet Haematol. 2024. PMID: 39067465 Clinical Trial.
Multiple lenses.
Baker RE. Baker RE. Science. 2024 May 24;384(6698):930. doi: 10.1126/science.adq5219. Epub 2024 May 23. Science. 2024. PMID: 38781363 No abstract available.
5,460 results